Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Tapentadol IR and ER can be converted to equivalent daily doses

Feb. 5, 2010

Tanezumab relieves pain in three chronic conditions

Feb. 5, 2010

SYN-115 enhances effects of levodopa in Parkinson's disease patients

Feb. 4, 2010

GI-4000 plus gemcitabine evaluated in ras mutation-bearing pancreas cancer

Feb. 3, 2010

MK-0646 added to gemcitabine and erlotinib active in advanced pancreatic cancer

Feb. 3, 2010

Perifosine plus capecitabine active in mCRC; phase III study planned

Feb. 3, 2010

PHY-906 beneficial when added to capecitabine in phase II pancreatic cancer trial

Feb. 3, 2010

Rilotumumab dose selected for randomized evaluation with panitumumab in mCRC

Feb. 2, 2010

Combination of pasireotide and everolimus feasible for neuroendocrine tumors

Feb. 2, 2010

Phase II data show everolimus monotherapy to be safe and active in metastatic gastric cancer

Feb. 2, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...